Belinostat for the treatment of peripheral T-cell lymphomas

Drugs of Today

Volumn 50, Issue 5, 2014, Pages 337-345

  McDermott, J ^a   Jimeno, Antonio ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Belinostat; Histone deacetylase 1 (HDAC1) inhibitors; Histone deacetylase 2 (HDAC2) inhibitors; Peripheral T cell lymphoma; PX 105684

Indexed keywords

BELINOSTAT; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 6; HISTONE H4; IBRITUMOMAB TIUXETAN; ISOTRETINOIN; PACLITAXEL; RITUXIMAB; WARFARIN; YTTRIUM 90;

ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CHROMATIN STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; EDEMA; ENZYME INHIBITION; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; LARGE CELL LYMPHOMA; LETHARGY; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; PARALYTIC ILEUS; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; PNEUMONIA; PRURITUS; QT PROLONGATION; RASH; RESPIRATORY DISTRESS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; VOMITING;

BELINOSTAT; HISTONE DEACETYLASE 1 (HDAC1) INHIBITORS; HISTONE DEACETYLASE 2 (HDAC2) INHIBITORS; PERIPHERAL T-CELL LYMPHOMA; PX-105684;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, T-CELL, PERIPHERAL; SULFONAMIDES;

EID: 84901706232     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.5.2138703     Document Type: Article

References (40)

1. Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P., Weisenburger, D.D., Linet, M.S. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107(1): 265-76. (Pubitemid 43053551)
2. Jaffe, E.S. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009: 523-31.
3. Vose, J., Armitage, J., Weisenburger, D., International, T.C.L.P. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26(25): 4124-30.
4. Foss, F.M., Zinzani, P.L., Vose, J.M., Gascoyne, R.D., Rosen, S.T., Tobinai, K. Peripheral T-cell lymphoma. Blood 2011, 117(25): 6756-67.
5. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329(14): 987-94.
6. Gutierrez-Garcia, G., Garcia-Herrera, A., Cardesa, T. et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol 2011, 22(2): 397-404.
7. AbouYabis, A.N., Shenoy, P.J., Flowers, C., Lechowicz, M.J. Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: A comprehensive meta-analysis. Blood 2007, 110(11): 1011a-2a.
8. Escalon, M.P., Liu, N.S., Yang, Y., Hess, M., Walker, P.L., Smith, T.L., Dang, N.H. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005, 103(10): 2091-8. (Pubitemid 40605117)
9. Mak, V., Hamm, J., Chhanabhai, M. et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013, 31(16): 1970-6.
10. Lund, A.H., van Lohuizen, M. Epigenetics and cancer. Genes Dev 2004, 18(19): 2315-35. (Pubitemid 39310518)
11. Thiagalingam, S., Cheng, K.H., Lee, H.J., Mineva, N., Thiagalingam, A., Ponte, J.F. Histone deacetylases: Unigue players in shaping the epigenetic histone code. Ann NY Acad Sci 2003, 983: 84-100. (Pubitemid 36399322)
12. Baylin, S.B., Ohm, J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006, 6(2): 107-16. (Pubitemid 43361543)
13. Pandolfi, P.P. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother Pharmacol 2001, 48(Suppl. 1): S17-9. (Pubitemid 33738366)
14. Marks, P.A., Jiang, X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005, 4(4): 549-51. (Pubitemid 41359778)
15. Lindemann, R.K., Gabrielli, B., Johnstone, R.W. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 2004, 3(6): 779-88. (Pubitemid 40187911)
16. Bolden, J.E., Peart, M.J., Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5(9): 769-84. (Pubitemid 44348499)
17. Marquard, L., Poulsen, C.B., Gjerdrum, L.M. et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 2009, 54(6): 688-98.
18. Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R., Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12(10): 1247-52. (Pubitemid 350106355)
19. th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 8546.
20. st Annu Meet Am Soc Hematol (December 5-8, New Orleans) 2009] 2009, 114(22): Abst 1657.
21. Plumb, J.A., Williams, R.J., Finn, P.W. et al. Inhibition of tumor cell growth in vitro and in vivo by the histone deacetylase inhibitor PXD101. Proc Am Assoc Cancer Res (AACR) 2002, 43: Abst 1653.
22. Plumb, J.A., Finn, P.W., Williams, R.J. et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003, 2(8): 721-8.
23. Steele, N.L., Plumb, J.A., Vidal, L. et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008, 14(3): 804-10. (Pubitemid 351231163)
24. Qian, X., LaRochelle, W.J., Ara, G. et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 2006, 5(8): 2086-95. (Pubitemid 44336581)
25. Buckley, M.T., Yoon, J., Yee, H. et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med 2007, 5: 49.
26. Tumber, A., Collins, L.S., Petersen, K.D. et al. The histone deacetylase inhibitor PXD101 synergises with 5-fiuorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 2007, 60(2): 275-83. (Pubitemid 46742543)
27. Feng, R., Oton, A., Mapara, M.Y., Anderson, G., Belani, C., Lentzsch, S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007, 139(3): 385-97. (Pubitemid 47512171)
28. Steele, N., Plumb, J., Vidal, L. et al. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother Pharmacol 2011, 67(6): 1273-9.
29. th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 3531.
30. Wang, L.Z., Ramirez, J., Yeo, W. et al. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One 2013, 8(1): e54522.
31. Gimsing, P., Hansen, M., Knudsen, L.M., Knoblauch, P., Christensen, I.J., Ooi, C.E., Buhl-Jensen, P. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 2008, 81(3): 170-6.
32. nd Annu Meet Am Soc Hematol (December 4-7, Orlando) 2010] 2010, 116(21): Abst 1787.
33. Cheson, B.D., Pfistner, B., Juweid, M.E. et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25(5): 579-86. (Pubitemid 350002966)
34. st Annu Meet Am Soc Hematol (December 5-8, New Orleans) 2009] 2009, 114(22): Abst 920.
35. th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst 8507.
36. Novotny-Diermayr, V., Nayagam, V.M., Hentze, H.H. et al. A robust and quantitative biomarker assay for SB939, a potent, orally-active HDAC inhibitor. EJC Suppl 2008, 6(12): 28-9.
37. Stimson, L., La Thangue, N.B. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 2009, 280(2): 177-83.
38. Fotheringham, S., Epping, M.T., Stimson, L. et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 2009, 15(1): 57-66.
39. Khan, O., Fotheringham, S., Wood, V. et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A 2010, 107(14): 6532-7.
40. Dejligbjerg, M., Grauslund, M., Christensen, I.J., Tjornelund, J., Buhl Jensen, P., Sehested, M. Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. Cancer Biomark 2008, 4(2): 101-9. (Pubitemid 351712270)